Answers are grounded in this paper and cite their sources.
Retrospective analysis reveals tumor sidedness and co-mutations impact outcomes in BRAF V600E mCRC, suggesting future stratification strategies.
e15608 Background: BRAF V600E-mutated pMMR/MSS mCRC has poor prognosis. However, real-world outcomes are heterogeneous and have recently improved with the introduction of front-line BRAF inhibitor-based combinations. We investigated the prognostic role of clinical and molecular features in this subset of mCRC, focusing on tumor sidedness and recurrent co-mutations. Methods: This retrospective single-center study included consecutive patients (pts) with pMMR/MSS BRAF V600E mCRC treated between September 2010 and September 2025 at the Veneto Institute of Oncology-IRCCS. Overall survival (OS) was estimated using Kaplan-Meier method and compared by log-rank test. Cox proportional hazards models were used for uni- and multivariable analyses. Next-generation sequencing data were available in a molecularly profiled subcohort. Results: Among 200 pts, 83 (42%) had left-sided primary tumor. Median age was 64 years (IQR 53 - 71) and ECOG PS was 0 in 51% of pts. Primary tumor was resected in 77% and disease presentation was synchronous in 74% of pts. Liver metastases (mts) were present in 64% of pts. Left-sided tumors occurred at a younger age than right-sided (median 58 vs 68 years; p = 0.001) and more frequently presented as early-onset disease (≤50 years: 33% vs 14%; p = 0.001). After median follow-up of 84.7 months (mo), median OS (mOS) in the cohort was 18.6 mo. Right-sided tumors showed significantly longer OS compared with left-sided tumors (22.6 vs 14.8 mo; p = 0.019). Multivariable analysis identified left-sided tumor (HR 1.54, 95% CI 1.12–2.08; p = 0.007), synchronous disease (HR 1.47, 95% CI 1.01–2.12; p = 0.042), unresected primary tumor (HR 1.49, 95% CI 1.03–2.17; p = 0.036), and ECOG performance status ≥1 (HR 1.37, 95% CI 1.01–1.85; p = 0.044) as independent factors associated with worse OS. Liver mts and early-onset disease had no prognostic role in univariable analyses and were not included in multivariable model. Among 80 molecularly profiled pts, BRAF V600E was confirmed in 100% of pts (n = 80). Frequent co-mutations included TP53 (76%), APC (36%), and SMAD4 (20%), RNF43 (17%), PIK3CA (15%), PTEN (15%), IRS2 amplification (11%) and MYC amplification (11%). PIK3CA and SMAD4 mutations were enriched in left-sided tumors (26% vs 7%, p = 0.014; 35% vs 11%, p = 0.008). No significant gene enrichment was observed in early vs average onset tumors. PIK3CA mutations were associated with worse OS compared with wild-type tumors (19.0 vs 27.2 mo; HR 2.32, 95% CI 1.22–4.04; p = 0.010). No significant prognostic impact was observed for APC, TP53, SMAD4, RNF43, PTEN, MYC and IRS2 too. Conclusions: Tumor sidedness is an independent prognostic factor in pMMR/MSS BRAF-mutant mCRC, with worse outcomes observed in left-sided tumors. PIK3CA co-mutations are enriched in left-sided disease and may contribute to unfavorable prognosis, suggesting their potential role in future stratification strategies.
No takes yet. Share an insight, caveat, or question.
Perissinotto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: